Share. Connect. Create. Grow. · Socialiya
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celia...

BUSINESS NEWS July 27, 2026

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.

13 views 0 likes 0 comments
Share:
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.

Author: Fierce Biotech

Read Original Article

Related News

Latest News

Advertisement

Top Categories

Advertisement
Advertisement
Advertisement
Advertisement